Complete Filing Data
OS Therapies Inc reported Stockholders Equity of -$6.10 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean OS Therapies Inc did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income Loss | -$28.8M | -$8.9M | -$7.8M |
| Research And Development Expense | $16.4M | $2.8M | $3.2M |
| Operating Income Loss | -$28.7M | -$6.8M | -$4.3M |
| Nonoperating Income Expense | -$48.1K | -$2.1M | -$3.4M |
| Net Income Loss Available To Common Stockholders Basic | -$28.8M | -$8.9M | -$7.9M |
| General And Administrative Expense | $12.3M | $4.0M | $1.1M |
| Interest Expense Nonoperating | $2.1M | $3.4M | |
| Interest Expense |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$6.9M | -$4.5M | -$3.9M | -$2.9M | -$1.6M | -$1.5M | -$2.0M | -$2.5M | -$1.8M |
| Research And Development Expense | $3.8M | $2.5M | $1.3M | $1.2M | $396.6K | $361.8K | $454.5K | $992.9K | $753.8K |
| Operating Income Loss | -$6.9M | -$4.8M | -$5.0M | -$2.4M | -$779.8K | -$630.2K | -$622.2K | -$1.5M | -$1.0M |
| Nonoperating Income Expense | $65.00 | $302.1K | $1.1M | -$437.8K | -$777.7K | -$828.8K | -$1.4M | -$989.7K | -$798.9K |
| Net Income Loss Available To Common Stockholders Basic | -$6.9M | -$4.5M | -$3.9M | -$2.9M | -$1.6M | -$1.5M | -$2.0M | -$2.5M | -$1.9M |
| General And Administrative Expense | $3.1M | $2.3M | $3.7M | $1.2M | $383.2K | $268.4K | $167.7K | $522.5K | $294.2K |
| Interest Expense Nonoperating | $437.8K | $777.7K | $828.8K | $1.4M | $989.7K | ||||
| Interest Expense | $828.8K | $798.9K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity * | -$6.1M | -$3.3M | -$24.0M | -$17.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $269.8K | $5.5M | $39.0K | $171.5K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$5.3M | $5.5M | -$132.5K | |
| Preferred Stock Dividends And Other Adjustments | $31.3K | $125.0K | ||
| Retained Earnings Accumulated Deficit | -$67.2M | -$38.4M | -$29.5M | |
| Liabilities Noncurrent | $100.0K | $100.0K | $100.0K | |
| Liabilities Current | $11.8M | $4.6M | $24.7M | |
| Liabilities And Stockholders Equity | $6.8M | $5.5M | $798.1K | |
| Liabilities | $11.9M | $4.7M | $24.8M | |
| Dividends Preferred Stock | $31.3K | $125.0K | ||
| Dividends Payable Current | $375.0K | $375.0K | $343.8K | |
| Assets Current | $332.9K | $5.5M | $790.0K | |
| Assets | $6.8M | $5.5M | $798.1K | |
| Accrued Liabilities Current | $1.4M | $521.0K | $162.5K | |
| Accounts Payable Current | $9.9M | $1.7M | $2.7M | |
| Accrued Payroll And Payroll Taxes Related Party | $36.8K | $97.3K | $112.1K | |
| Deferred Offering Costs Recorded As Accounts Payable | $751.1K | $142.7K | ||
| Common Stock Value | $37.1K | $20.9K | $5.3K | |
| Accrued Payroll Taxes Current | $1.3K | $33.5K | ||
| Property Plant And Equipment Net | $2.5K | $5.3K | $8.1K | |
| Noncash Or Part Noncash Acquisition Payables Assumed1 | $31.3K | $125.0K | ||
| Makewhole Stock Liability Current | $130.0K | |||
| Deferred Costs Current | $751.1K | |||
| Accrued Intereston Convertible Notes Current | $2.0M | |||
| Preferred Stock Value | $1.3K | |||
| Dividends Payable | ||||
| Conversion Of Preferred Stock To Common Stock | $1.3K | |||
| Temporary Equity Value Excluding Additional Paid In Capital | $1.1M | $4.1M | ||
| Temporary Equity Carrying Amount Attributable To Parent | $1.1M | $4.1M | ||
| Finite Lived Intangible Assets Net | ||||
| Deferred Offering Costs |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $3.6M | $4.9M | -$4.2M | -$3.3M | -$707.1K | -$27.1M | -$25.5M | -$24.0M | -$22.5M | -$21.3M | -$18.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.9M | $2.8M | $3.0M | $1.9M | $94.9K | $100.2K | $16.1K | $49.2K | $355.2K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$2.6M | $61.2K | $183.7K | ||||||||
| Preferred Stock Dividends And Other Adjustments | $31.3K | $31.3K | $31.3K | $31.3K | |||||||
| Retained Earnings Accumulated Deficit | -$53.7M | -$46.8M | -$42.3M | -$35.4M | -$32.6M | -$31.0M | |||||
| Liabilities Noncurrent | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | |||||
| Liabilities Current | $4.1M | $3.5M | $3.5M | $2.6M | $28.3M | $26.5M | |||||
| Liabilities And Stockholders Equity | $9.0M | $10.3M | $4.2M | $2.0M | $1.3M | $1.0M | |||||
| Liabilities | $4.2M | $3.6M | $3.6M | $2.7M | $28.4M | $26.6M | |||||
| Dividends Preferred Stock | $31.3K | $31.3K | $31.3K | $31.3K | |||||||
| Dividends Payable Current | $375.0K | $375.0K | $375.0K | $375.0K | $375.0K | $375.0K | |||||
| Assets Current | $2.3M | $3.6M | $4.1M | $2.0M | $1.3M | $1.0M | |||||
| Assets | $9.0M | $10.3M | $4.2M | $2.0M | $1.3M | $1.0M | |||||
| Accrued Liabilities Current | $395.5K | $380.3K | $364.4K | $296.4K | $187.5K | $162.5K | |||||
| Accounts Payable Current | $3.4M | $2.7M | $1.6M | $1.8M | $2.9M | $2.8M | |||||
| Accrued Payroll And Payroll Taxes Related Party | $10.1K | $30.4K | $42.7K | ||||||||
| Deferred Offering Costs Recorded As Accounts Payable | $42.3K | $95.3K | |||||||||
| Common Stock Value | $33.3K | $29.7K | $21.3K | $21.2K | $6.0K | $12.0K | |||||
| Accrued Payroll Taxes Current | $614.00 | $270.00 | $881.00 | $84.0K | $49.4K | ||||||
| Property Plant And Equipment Net | $3.2K | $3.9K | $4.6K | $6.7K | $6.7K | ||||||
| Noncash Or Part Noncash Acquisition Payables Assumed1 | $31.3K | ||||||||||
| Makewhole Stock Liability Current | $130.0K | $130.0K | $130.0K | ||||||||
| Deferred Costs Current | $1.2M | ||||||||||
| Accrued Intereston Convertible Notes Current | $2.5M | ||||||||||
| Preferred Stock Value | |||||||||||
| Dividends Payable | $31.3K | $31.3K | |||||||||
| Conversion Of Preferred Stock To Common Stock | |||||||||||
| Temporary Equity Value Excluding Additional Paid In Capital | $1.1M | $1.8M | $4.8M | ||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $1.1M | $1.8M | $4.8M | ||||||||
| Finite Lived Intangible Assets Net | $7.4K | $8.1K | |||||||||
| Deferred Offering Costs | $941.3K | $751.1K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$14.2M | -$7.3M | -$3.0M |
| Net Cash Provided By Used In Financing Activities | $9.4M | $12.8M | $2.9M |
| Increase Decrease In Accounts Payable | $8.3M | -$1.1M | $1.3M |
| Increase Decrease In Employee Related Liabilities | -$48.4K | -$280.3K | |
| Proceeds From Convertible Debt | $1.5M | $3.2M | |
| Increase Decrease In Accrued Liabilities | $894.0K | $358.5K | $147.5K |
| Increase Decrease In Accrued Interest Receivable Net | -$613.6K | -$802.5K | |
| Payments Of Stock Issuance Costs | $284.2K | ||
| Net Cash Provided By Used In Investing Activities | -$466.4K | $1.1K | |
| Proceeds From Short Term Debt | $250.0K | ||
| Share Based Compensation | $4.3M | $268.3K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q2 2025 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$3.4M | -$641.7K | -$428.2K | |
| Net Cash Provided By Used In Financing Activities | $1.1M | $703.0K | $610.8K | |
| Increase Decrease In Accounts Payable | -$45.7K | $41.5K | $446.0K | |
| Increase Decrease In Employee Related Liabilities | -$97.0K | -$53.6K | $47.0K | |
| Proceeds From Convertible Debt | $751.0K | $775.0K | ||
| Increase Decrease In Accrued Liabilities | -$156.6K | $10.0K | ||
| Increase Decrease In Accrued Interest Receivable Net | -$250.0K | -$182.8K | ||
| Payments Of Stock Issuance Costs | $148.0K | $164.2K | ||
| Net Cash Provided By Used In Investing Activities | -$173.6K | $1.1K | ||
| Proceeds From Short Term Debt | $100.0K | |||
| Share Based Compensation | $905.2K | $941.3K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Earnings Per Share Diluted | $-0.98 | $-1.28 | $-1.46 |
| Earnings Per Share Basic | $-0.98 | $-1.28 | $-1.46 |
| Common Stock Shares Authorized | 150.0M | 150.0M | 50.0M |
| Weighted Average Number Of Diluted Shares Outstanding | 29.3M | 7.0M | |
| Common Stock Shares Outstanding | 37.1M | 20.9M | 5.3M |
| Preferred Stock Shares Authorized | 5.0M | 5.0M | 5.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Weighted Average Number Of Shares Outstanding Basic | 12.4M | 5.4M | |
| Common Stock Shares Issued | 37.1M | 20.9M | 5.3M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | |
| Conversion Of Stock Shares Issued1 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-0.21 | $-0.19 | $-0.18 | $-0.18 | $-0.26 | $-0.25 | $-0.38 | $-0.47 | |||
| Earnings Per Share Basic | $-0.21 | $-0.19 | $-0.18 | $-0.18 | $-0.26 | $-0.25 | $-0.38 | $-0.47 | |||
| Common Stock Shares Authorized | 50.0M | 50.0M | 50.0M | 50.0M | 50.0M | 50.0M | |||||
| Weighted Average Number Of Diluted Shares Outstanding | 32.0M | 25.1M | 21.2M | 15.9M | 6.0M | 6.0M | 5.3M | 5.3M | |||
| Common Stock Shares Outstanding | 33.3M | 29.7M | 21.3M | 21.2M | 6.0M | 12.0M | |||||
| Preferred Stock Shares Authorized | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | |||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Weighted Average Number Of Shares Outstanding Basic | 15.9M | 6.0M | 5.3M | 5.3M | |||||||
| Common Stock Shares Issued | 33.3M | 29.7M | 21.3M | 21.2M | 6.0M | 12.0M | |||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.3M | 1.3M | |||
| Conversion Of Stock Shares Issued1 | 700.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2021 |
|---|---|---|---|---|
| Notes Issued1 | $750.5K | $1.5M | ||
| Amortization Of Financing Costs And Discounts | $1.4M | $2.6M | ||
| Depreciation | $2.8K | $4.2K | ||
| Investment Income Interest | $249.00 | $2.00 | ||
| Additional Paid In Capital | $35.1M | $5.5M | ||
| Makewhole Expense | $116.7K | |||
| Redemption Premium Current | $4.6M | |||
| Reimbursable Grant Amount Non Current | ||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $24.8M | |||
| Shareholder Loan Repayment | $1.1K | |||
| TEDCO Grant Non Current | $100.0K | $100.0K | $100.0K | |
| Stock Issued During Period Value New Issues | $4.5M | |||
| Conversion Of Stock Amount Converted1 | $130.0K | |||
| Stock Issued During Period Value Other | $8.5K | $408.4K | ||
| Stock Issued During Period Value Issued For Services | $25.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Notes Issued1 | $475.5K | $350.0K | |||||||
| Amortization Of Financing Costs And Discounts | -$1.1M | $578.7K | $616.2K | ||||||
| Depreciation | $695.00 | $695.00 | $100.00 | ||||||
| Investment Income Interest | $65.00 | $64.00 | $66.00 | $1.00 | $1.00 | ||||
| Additional Paid In Capital | $34.7M | $5.5M | $5.5M | ||||||
| Makewhole Expense | $116.7K | ||||||||
| Redemption Premium Current | $5.3M | $5.1M | |||||||
| Reimbursable Grant Amount Non Current | $100.0K | $100.0K | $100.0K | ||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $2.5M | $24.8M | $700.0K | ||||||
| Shareholder Loan Repayment | |||||||||
| TEDCO Grant Non Current | $100.0K | $100.0K | $100.0K | $100.0K | |||||
| Stock Issued During Period Value New Issues | $568.2K | $4.5M | |||||||
| Conversion Of Stock Amount Converted1 | $700.0K | ||||||||
| Stock Issued During Period Value Other | |||||||||
| Stock Issued During Period Value Issued For Services | $239.3K | $10.0K | $1.4M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.